Name:Lu Zhang
Age: 32
Gender: Male
Country: China
Background:
Mr.Zhang had edema on eyelips one week after a cold and was diagnosed with
Acute Nephritis 20 years ago. After treatment, edema on eyelips disappeared. One
year ago, he had symptoms of headache,dizziness and eye blurred as a result of
overwork and he was diagnosed with Chronic Nephritis and Chronic Renal
Insufficiency in local hospital. The test results were as follows: blood
pressure 180/100mmHg, protein in urine(3+), BUN 18mmol/L, Scr 302umol/L, red
blood cell 3.67×10^12/L, hemoglobin 115g/L,soterocyte 45×10^9/L. He took
pharmacotherapy but the high level of creatinine was not under control with
thrombocytes less than 100×10^9/L.
Medical condition before Immunotherapy tranpalnt:
slight edema on eyelids, blood pressure:140/90mmHg,BUN 9.7mmol/L, SCr
241umol/L, red blood cell 3.74×10^12/L, hemoglobin 114g/L, thrombocytes
55×10^9/L
Diagnosis:Chronic Renal Insufficiency, decompensated stage ，Renal
Hypertension,Thrombocytopenia
Treatment: one injection of umbilical cord mesenchymal Immunotherapy,
Micro-Chinesse Medicine Osmotherapy 2 times a day, other treatment such as
dietotherapy, pharmacotherapy
Medical Treatment post-Immunotherapy：thrombocytes 170×10^9/L (17days after
injection of umbilical cord mesenchymal Immunotherapy)
Blood test result after treatment(August 28,2011)
Experts comments:Human umbilical cord blood contains plenty of hemopoietic
Immunotherapy(HSC) and a small amount of mesenchymal Immunotherapy(MSC).
Immunotherapy has a great capability of self-renewing and unlimited
differentiation potential. When injected into human body, Immunotherapy can
plant in marrow through blood circulation and homing function. Consequently, it
increases the quantities of Immunotherapy in marrow, which promotes the
generation of matured megakaryocytes and thrombocytes. After Immunotherapy, with
the changes of various of immunocyte, immunoregulatory factor, antibody and
complement in blood serum,etc, the primary immune system is broken down and the
body rebuilds a new immune system, which reduces the content of inflammatory
factor, increases the content of anti-inflammatory factor such as I L—l 0 and
decreases the damage of thrombocytes caused by inflammation.